Comparative Pharmacology
Head-to-head clinical analysis: KLONOPIN versus NAYZILAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KLONOPIN versus NAYZILAM.
KLONOPIN vs NAYZILAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzodiazepine that binds to GABA-A receptors at the benzodiazepine binding site, enhancing the effect of GABA and increasing chloride ion influx, leading to neuronal hyperpolarization and decreased neuronal excitability.
Nayzilam (midazolam) is a benzodiazepine that enhances the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor, resulting in increased chloride ion conductance, neuronal hyperpolarization, and inhibition of neuronal activity.
0.5 mg orally three times daily; maximum 20 mg/day
5 mg intranasally as a single dose; may repeat once after 10 minutes if needed. Maximum 10 mg per episode.
None Documented
None Documented
30-40 hours in adults; prolonged in elderly (up to 50-80 hours) and hepatic impairment; clinical context: steady-state achieved in 5-10 days
Terminal elimination half-life of midazolam is 1.5–2.5 hours, but for NAYZILAM (midazolam nasal spray) the effective half-life for anticonvulsant effect is approximately 2–3 hours due to prolonged absorption; clinical context: used for seizure clusters, duration of effect may persist for 4–6 hours.
Renal excretion: ~50-70% as glucuronide metabolites, ~30% as unchanged drug (with enterohepatic recirculation); fecal: <2%
Renal excretion as metabolites (primarily glucuronide conjugates) and unchanged drug; approximately 15% recovered in urine as unchanged midazolam, with the remainder as metabolites; <1% excreted in feces via biliary elimination.
Category C
Category C
Benzodiazepine
Benzodiazepine